Sylvain Celanire, CEO will be available for one-on-one meetings throughout the 3-day conference. 

To schedule a meeting, please reach out to us via: Click here

We will be sharing the latest development on our small molecule HDAC6 inhibitor projects portfolio, including our peripheral-restricted clinical candidate AGT100216 advancing into regulatory development for Charcot-Marie-Tooth disease and Chemotherapy-induced neuropathies, as well as our brain penetrant selective HDAC6 inhibitor program for neurodegenerative diseases, including ALS.

Agenda of Bio-Europe: Click here